Single-cell foundation models predict durable CAR T response despite imperfect cell annotation

CD19-targeted chimeric antigen receptor (CAR) T cell therapy achieves high initial response rates in B-cell acute lymphoblastic leukemia (B-ALL), yet half of patients relapse within one year. Pre-infusion product composition decoded by single-cell RNA sequencing (scRNA-seq) carries information predictive of long-term CAR T persistence, but extracting this information from individual patients typically requires highly sophisticated bioinformatics expert annotation, limiting clinical translation. Here, we evaluate whether single-cell foundation models (scFMs) can extract clinically actionable information from engineered CAR T products. We applied four scFMs (scGPT, scFoundation, CellPLM and UCE), including fine-tuned versions of scGPT and scFoundation, to paired basal and CD19-stimulated pre-infusion CAR T products from 33 pediatric patients with B-ALL. Although annotation accuracy declined relative to healthy peripheral blood references, scFM-derived cell composition stratified patients with long-duration B-cell aplasia with a leave-one-out cross-validated area under the receiver operating characteristic curve of 0.879 (95% confidence interval, 0.742–0.986). Notably, foundation-model-identified cell proportion analysis matched or exceeded expert annotations for several predictive features, demonstrating that accurate clinical prediction may not require perfect per-cell annotation to begin with. CD8+XCL1/2+ cells were further identified as the biomarker consistently associated with durable CAR T persistence across models under CD19 stimulation, whereas other candidate populations showed limited reproducibility. Finally, we translate these findings into a demo clinical decision-support tool that predicts the probability of sustained CAR T persistence from pre-infusion CAR T scRNA-seq data.